 Suzanne Paul
Concepts (56)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 5 | 2016 | 390 | 0.360 |
Why?
| | Infectious Disease Transmission, Vertical | 6 | 2016 | 182 | 0.350 |
Why?
| | Anti-HIV Agents | 4 | 2016 | 775 | 0.250 |
Why?
| | Drug Resistance, Viral | 2 | 2016 | 116 | 0.190 |
Why?
| | HIV Infections | 5 | 2016 | 2828 | 0.170 |
Why?
| | HIV | 2 | 2010 | 234 | 0.140 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.130 |
Why?
| | Lopinavir | 1 | 2016 | 30 | 0.130 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 41 | 0.130 |
Why?
| | Pediatric Obesity | 1 | 2023 | 590 | 0.120 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 69 | 0.120 |
Why?
| | Ritonavir | 1 | 2016 | 74 | 0.120 |
Why?
| | Chickenpox Vaccine | 1 | 2015 | 73 | 0.120 |
Why?
| | Chickenpox | 1 | 2015 | 83 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 113 | 0.110 |
Why?
| | Telemedicine | 1 | 2023 | 852 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2015 | 624 | 0.090 |
Why?
| | HIV-1 | 1 | 2016 | 863 | 0.080 |
Why?
| | Anti-Retroviral Agents | 1 | 2011 | 233 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 1062 | 0.070 |
Why?
| | Pregnancy | 5 | 2016 | 6729 | 0.050 |
Why?
| | Zidovudine | 2 | 2015 | 78 | 0.050 |
Why?
| | Lamivudine | 2 | 2015 | 63 | 0.050 |
Why?
| | Weight Reduction Programs | 1 | 2023 | 116 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2023 | 15510 | 0.040 |
Why?
| | Child, Preschool | 3 | 2023 | 10997 | 0.040 |
Why?
| | Prevalence | 2 | 2016 | 2710 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2016 | 6032 | 0.040 |
Why?
| | Viral Load | 2 | 2010 | 464 | 0.030 |
Why?
| | Infant | 3 | 2016 | 9395 | 0.030 |
Why?
| | Female | 8 | 2023 | 72816 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2023 | 978 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 17 | 0.030 |
Why?
| | Adolescent | 3 | 2023 | 21385 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2015 | 165 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1616 | 0.030 |
Why?
| | Child | 3 | 2023 | 21819 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 146 | 0.030 |
Why?
| | Male | 5 | 2023 | 67330 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 170 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 198 | 0.030 |
Why?
| | United States | 2 | 2023 | 14691 | 0.020 |
Why?
| | Humans | 8 | 2023 | 136803 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 605 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2010 | 269 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2010 | 271 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 412 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 363 | 0.020 |
Why?
| | Kinetics | 1 | 2010 | 1664 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 654 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 5704 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5424 | 0.010 |
Why?
| | Prospective Studies | 1 | 2016 | 7573 | 0.010 |
Why?
| | Adult | 3 | 2011 | 37643 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 3947 | 0.010 |
Why?
| | Risk Factors | 1 | 2011 | 10332 | 0.010 |
Why?
|
|
Paul's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|